Table 1. The correlation of leptin with cancer patient survival.
| Symbol | Cance type | Prognosis | Endpoint | p value | Case | Dataset/Cohort | Method | Probe ID |
|---|---|---|---|---|---|---|---|---|
| LEP | Bladder urothelial carcinoma | - | Overall survival | N.S. | 390 | TCGA | RNA Seq | |
| LEP | Glioblastoma multiforme | - | Overall survival | N.S. | 538 | TCGA | RNA Seq | |
| LEP | Breast invasive carcinoma | Poor | Overall survival | 0.0013 | 962 | TCGA | RNA Seq | |
| LEP | Cervical squamous cell carcinoma | - | Overall survival | N.S. | 191 | TCGA | RNA Seq | |
| LEP | Colon and rectum adenocarcinoma | Poor | Overall survival | 0.025 | 467 | TCGA | RNA Seq | |
| LEP | Esophageal carcinoma | - | Overall survival | N.S. | 184 | TCGA | RNA Seq | |
| LEP | Head and neck squamous cell carcinoma | - | Overall survival | N.S. | 502 | TCGA | RNA Seq | |
| LEP | Acute myeloid leukemia | Poor | Overall survival | 1E-05 | 168 | TCGA | RNA Seq | |
| LEP | Kidney pan cancer | - | Overall survival | N.S. | 792 | TCGA | RNA Seq | |
| LEP | Liver hepatocellular carcinoma | Poor | Overall survival | 3E-05 | 361 | TCGA | RNA Seq | |
| LEP | Lung adenocarcinoma | - | Overall survival | N.S. | 475 | TCGA | RNA Seq | |
| LEP | Ovarian serous cystadenocarcinoma | - | Overall survival | N.S. | 578 | TCGA | RNA Seq | |
| LEP | Pancreatic adenocarcinoma | - | Overall survival | N.S. | 176 | TCGA | RNA Seq | |
| LEP | Prostate adenocarcinoma | - | Overall survival | N.S. | 497 | TCGA | RNA Seq | |
| LEP | Skin cutaneous melanoma | - | Overall survival | N.S. | 336 | TCGA | RNA Seq | |
| LEP | Stomach adenocarcinoma | - | Overall survival | N.S. | 352 | TCGA | RNA Seq | |
| LEP | Testicular germ cell tumors | - | Overall survival | N.S. | 133 | TCGA | RNA Seq | |
| LEP | Thymoma | - | Overall survival | N.S. | 118 | TCGA | RNA Seq | |
| LEP | Thyroid carcinoma | - | Overall survival | N.S. | 489 | TCGA | RNA Seq | |
| LEP | Uterine corpus endometrioid carcinoma | - | Overall survival | N.S. | 332 | TCGA | RNA Seq | |
| LEP | Breast cancer | Good | Overall survival | 0.037 | 1402 | E-MTAB-365, E-TABM-43, GSE: 11121, 12093, 12276, 1456, 16391, 16446, 16716, 17705, 17907, 18728, 19615, 20194, 20271, 2034, 20685, 20711, 21653, 2603, 26971, 2990, 31448, 31519, 32646, 3494, 37946, 41998, 42568, 45255, 4611, 5327, 6532, 7390, 9195 | Array | 207092_at |
| LEP | Gastric cancer | Poor | Overall survival | 0.0002 | 876 | GSE: 14210, 15459, 22377, 29272, 51105, 62254 | Array | 207092_at |
| LEP | Soft tissue cancer | Good | Distant recurrence free survival | 0.0006 | 140 | GSE30929 | Array | 207092_at |
| LEP | Ovarian cancer | Poor | Overall survival | 0.0051 | 278 | GSE9891 | Array | 207092_at |
| LEP | Colon rectal cancer | Poor | Disease specific survival | 0.0165 | 55 | GSE17537 | Array | 207092_at |
| LEP | Brain cancer (Glioma) | Poor | Overall survival | 0.046 | 74 | GSE4412-GPL96 | Array | 207092_at |
| LEP | Breast cancer | Poor | Distant metastasis free survival | 0.0489 | 200 | GSE11121 | Array | 207092_at |
Survival data was collected from database SurvExpress, TCGA and Kaplan Meier-plotter.
LEP: leptin. N.S.: no significance.